-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-503335-18-00
1
2022-07-29
Chronic myeloid leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-511780-28-00
4
2022-05-05
Patients with presumed and previously untreated advanced stage ovarian
-
2024-518243-38-00
5
2022-04-20
Fecal incontinence in female and male patients
-
2022-502434-10-00
4
2022-02-22
Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a
typ
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-514068-14-00
9
2021-10-12
leptomeningeal disease
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-504888-16-00
9
2020-10-05
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-510964-21-00
9
2019-09-12
Glioblastoma
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma